The global burden of IBD: from 2015 to 2025
- PMID: 26323879
- DOI: 10.1038/nrgastro.2015.150
The global burden of IBD: from 2015 to 2025
Abstract
Over 1 million residents in the USA and 2.5 million in Europe are estimated to have IBD, with substantial costs for health care. These estimates do not factor in the 'real' price of IBD, which can impede career aspirations, instil social stigma and impair quality of life in patients. The majority of patients are diagnosed early in life and the incidence continues to rise; therefore, the effect of IBD on health-care systems will rise exponentially. Moreover, IBD has emerged in newly industrialized countries in Asia, South America and Middle East and has evolved into a global disease with rising prevalence in every continent. Understanding the worldwide epidemiological patterns of IBD will prepare us to manage the burden of IBD over time. The goal of this article is to establish the current epidemiology of IBD in the Western world, contrast it with the increase in IBD in newly industrialized countries and forecast the global effects of IBD in 2025.
Similar articles
-
The Impact of Inflammatory Bowel Disease in Canada 2018: Epidemiology.J Can Assoc Gastroenterol. 2019 Feb;2(Suppl 1):S6-S16. doi: 10.1093/jcag/gwy054. Epub 2018 Nov 2. J Can Assoc Gastroenterol. 2019. PMID: 31294381 Free PMC article.
-
The burden of inflammatory bowel disease in Europe.J Crohns Colitis. 2013 May;7(4):322-37. doi: 10.1016/j.crohns.2013.01.010. Epub 2013 Feb 8. J Crohns Colitis. 2013. PMID: 23395397 Review.
-
Evolving Epidemiology of IBD.Curr Gastroenterol Rep. 2019 Jul 23;21(8):40. doi: 10.1007/s11894-019-0705-6. Curr Gastroenterol Rep. 2019. PMID: 31338613 Review.
-
Effect of aging on healthcare costs of inflammatory bowel disease: a glimpse into the future.Inflamm Bowel Dis. 2014 Apr;20(4):637-45. doi: 10.1097/01.MIB.0000442677.55051.03. Inflamm Bowel Dis. 2014. PMID: 24518606
-
Inflammatory bowel disease: a Canadian burden of illness review.Can J Gastroenterol. 2012 Nov;26(11):811-7. doi: 10.1155/2012/984575. Can J Gastroenterol. 2012. PMID: 23166905 Free PMC article. Review.
Cited by
-
Hospitalization and surgery rates in patients with inflammatory bowel disease in Brazil: a time-trend analysis.BMC Gastroenterol. 2021 Apr 27;21(1):192. doi: 10.1186/s12876-021-01781-x. BMC Gastroenterol. 2021. PMID: 33906627 Free PMC article.
-
Recent Research and Application Prospect of Functional Oligosaccharides on Intestinal Disease Treatment.Molecules. 2022 Nov 7;27(21):7622. doi: 10.3390/molecules27217622. Molecules. 2022. PMID: 36364447 Free PMC article. Review.
-
Oral Nanomedicines for siRNA Delivery to Treat Inflammatory Bowel Disease.Pharmaceutics. 2022 Sep 19;14(9):1969. doi: 10.3390/pharmaceutics14091969. Pharmaceutics. 2022. PMID: 36145716 Free PMC article. Review.
-
Inflammatory bowel disease biomarkers revealed by the human gut microbiome network.Sci Rep. 2023 Nov 8;13(1):19428. doi: 10.1038/s41598-023-46184-y. Sci Rep. 2023. PMID: 37940667 Free PMC article.
-
Alterations in metabolome and microbiome: new clues on cathelicidin-related antimicrobial peptide alleviates acute ulcerative colitis.Front Microbiol. 2024 Feb 6;15:1306068. doi: 10.3389/fmicb.2024.1306068. eCollection 2024. Front Microbiol. 2024. PMID: 38380090 Free PMC article.
References
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources